Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.62 |
| ▸ | CBFB | Q13951 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 4/20 | 0.50 |
| ▸ | METAP1 | P53582 | 3/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14891841 | 0.95 | ACHE (0.62) | ACHECBFBNPC1RAB9ARUNX1 | |
| SCHEMBL12289543 | 0.82 | CBFB (0.50) | CBFBNPC1RAB9ARUNX1PKM | |
| SCHEMBL21018152 | 0.81 | ACHE (0.81) | ACHENPC1RAB9APKMKDM4E | |
| SCHEMBL12289582 | 0.78 | ACHE (0.61) | ACHENPC1RAB9APKMKDM4E | |
| SCHEMBL21017583 | 0.78 | ACHE (0.64) | ACHENPC1RAB9APKMKDM4E | |
| SCHEMBL21017221 | 0.78 | ACHE (0.63) | ACHECHEK2 | |
| SCHEMBL20982555 | 0.78 | ACHE (0.59) | ACHECHEK2 | |
| SCHEMBL21018108 | 0.77 | ACHE (0.69) | ACHECHEK2 | |
| SCHEMBL21017655 | 0.77 | ACHE (0.65) | ACHENPC1RAB9AKDM4ELMNA | |
| SCHEMBL21017232 | 0.77 | ACHE (0.77) | ACHECHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | ACHE 3919/4885CBFB 688/4885NPC1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.